16152-51-5Relevant articles and documents
PHENYL-TRIAZOLO-PYRIDINE COMPOUNDS
-
Paragraph 0045, (2017/02/24)
The present invention provides a compound of the Formula (I) below: wherein R1 is selected from the group consisting of H, CH3, CN, —CH2CN, —C(CH3)2CN, F, Cl, and Br; R2 is selected from the group consisting of H, —O(C1-C3alkylene)R4, —CH2CN, CN, —OCH3, CF2, —C(CH3)2CN, —C(CH3)2, —S(O)2CH3, —S(O)2NH2, and —OCF2; R3 is selected from the group consisting of H, CH3, and —OCH3; and R4 is selected from the group consisting of H, —C(CH3)2CN, —OCH3, —S(O)2CH3, CN, and —C(CH3)2OH; or a pharmaceutical salt thereof, methods of treating type two diabetes using the compound and a process for preparing the compound.
PHENYL-TRIAZOLO-PYRIDINE COMPOUNDS
-
Page/Page column 13, (2015/07/23)
The present invention provides a compound of the Formula (I) below: wherein R1 is selected from the group consisting of H, CH3, CN, -CH2CN, -C(CH3)2CN, F, Cl, and Br; R2 is selected from the group consisting of H, -O(C1-C3alkylene)R4, -CH2CN, CN, - OCH3, CF2, -C(CH3)2CN, -C(CH3)2, -S(O)2CH3, -S(O)2NH2, and -OCF2; R3 is selected from the group consisting of H, CH3, and -OCH3; and R4 is selected from the group consisting of H, -C(CH3)2CN, -OCH3, -S(O)2CH3, CN, and -C(CH3)2OH; or a pharmaceutical salt thereof, methods of treating type two diabetes using the compound and a process for preparing the compound.
Metabolically stable tert-butyl replacement
Barnes-Seeman, David,Jain, Monish,Bell, Leslie,Ferreira, Suzie,Cohen, Scott,Chen, Xiao-Hui,Amin, Jakal,Snodgrass, Brad,Hatsis, Panos
, p. 514 - 516 (2013/07/26)
Susceptibility to metabolism is a common issue with the tert-butyl group on compounds of medicinal interest. We demonstrate an approach of removing all the fully sp3 C-Hs from a tert-butyl group: replacing some C-Hs with C-Fs and increasing the s-character of the remaining C-Hs. This approach gave a trifluoromethylcyclopropyl group, which increased metabolic stability. Trifluoromethylcyclopropyl-containing analogues had consistently higher metabolic stability in vitro and in vivo compared to their tert-butyl-containing counterparts.
N-aryl thienyl-, furyl-, and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
-
Page column 79, (2010/01/30)
Thienyl-, furyl- and pyrrolyl-sulfonamides and methods for modulating or altering the activity of the endothelin family of peptides are provided. In particular, N-(isoxazolyl)thienylsulfonamides, N-(isoxazolyl)furylsulfonamides and N-(isoxazolyl)pyrrolylsulfonamides and methods using these sulfonamides for inhibiting the binding of an endothelin peptide to an endothelin receptor by contacting the receptor with the sulfonamide are provided. Methods for treating endothelin-mediated disorders by administering effective amounts of one or more of these sulfonamides or prodrugs thereof that inhibit or increase the activity of endothelin are also provided.
Propanoic acid derivatives
-
, (2008/06/13)
Propanoic acid derivatives of formula (1) are described: Ar—X1—Ar1—Z—R??(1) in which Ar is a nitrogen base containing group; X1is linker atom or group; Ar1is an optionally substituted 5- or 6-membered nitrogen-containing aromatic or non-aromatic monocycle; Z is a group —CH(R13)CH2— [in which R13is an optionally substituted aliphatic, cycloaliphatic, heteroaliphatic, heterocycloaliphatic, aromatic or heteroaromatic group], —C(R12a)(R13)—CH(R12b)— [in which R12aand R12btogether with the carbon atoms to which they are attached form a C3-7cycloalkyl group] or C(R13)═CH—; R is a carboxylic acid (—CO2H) or a derivative or biostere thereof; and the salts, solvates, hydrates and N-oxides thereof. The compounds are able to inhibit the binding of αVintegrins to their ligands and are of use in the prophylaxis and treatment of immune or inflammatory disorders.
PHENYL SULFONAMIDE ENDOTHELIN ANTAGONISTS
-
, (2008/06/13)
Compounds of the formula STR1 inhibit the activity of endothelin. The symbols are defined as follows: R 1, R 2 and R. sup.3 are each independently(a) hydrogen, except that R. sup.1 is other than hydrogen;(b) alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl, aryloxy, aralkyl or aralkoxy, any of which may be substituted with Z 1, Z 2 and Z. sup.3 ;(c) halo;(d) hydroxyl;(e) cyano; (f) nitro; (g)--C(O)H or--C(O)R 6 ;(h)--CO 2 H or--CO 2 R 6 ; (i)--SH,--S(O) n R 6,--S(O) m--OH,--S(O) m--OR 6,--O--S(O) m--R 6,--O--S(O) m OH or--O--S(O) m--OR. sup.6 ;(j)--Z. sup.4--NR 7 R 8 ; or (k)--Z 4--N(R 11--Z 5--NR 9 R 10 ; and the remaining symbols are as defined in the specification.
